Lantern Pharma Inc.(LTRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LTRN Lantern Pharma Inc.

Post-Mkt 01-23 16:20:51 EST

3.46

-0.07

-1.98%

盘后3.46

+0.000.00%

16:10 EST

High3.59	Low3.41	Vol22.55K
Open3.53	D1 Closing3.53	Amplitude5.07%
Mkt Cap38.70M	Tradable Cap29.71M	Total Shares11.18M
T/O78.64K	T/O Rate0.26%	Tradable Shares8.59M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LTRN","market":"US","secType":"STK","nameCN":"Lantern Pharma Inc.","latestPrice":3.46,"timestamp":1769202000000,"preClose":3.53,"halted":0,"volume":22553,"hourTrading":{"tag":"盘后","latestPrice":3.46,"preClose":3.46,"latestTime":"16:10 EST","volume":322,"amount":1114.12,"timestamp":1769202605012,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.019830028328611853,"floatShares":8587400,"shares":11184423,"eps":-1.752393,"marketStatus":"Post-Mkt","change":-0.07,"latestTime":"01-23 16:20:51 EST","open":3.53,"high":3.5889,"low":3.41,"amount":78640.636675,"amplitude":0.05068,"askPrice":3.9,"askSize":5,"bidPrice":3.4,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-1.752393,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1769216400000},"marketStatusCode":4,"adr":0,"listingDate":1591848000000,"exchange":"NASDAQ","adjPreClose":3.53,"postHourTrading":{"tag":"盘后","latestPrice":3.46,"preClose":3.46,"latestTime":"16:10 EST","volume":322,"amount":1114.12,"timestamp":1769202605012,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.384437,"impliedVol":0.8981,"impliedVolPercentile":0.6096},"requestUrl":"/m/hq/s/LTRN/tweets","defaultTab":"tweets","newsList":[{"id":"2604113051","title":"BRIEF-Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation For Soft Tissue Sarcomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2604113051","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604113051?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:03","pubTimestamp":1768914209,"startTime":"0","endTime":"0","summary":"BRIEF-Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation For Soft Tissue SarcomasJan 20 (Reuters) - Lantern Pharma Inc LTRN.O:LANTERN PHARMA'S LP-284 RECEIVES FDA ORPHAN DRUG DESIGNATION FOR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nTUABHNFLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2604113996","title":"Lantern Pharma's Lp-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2604113996","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604113996?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:00","pubTimestamp":1768914003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nTUABHNFLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LTRN"],"gpt_icon":0},{"id":"2603955592","title":"Lantern Pharma’s treatment of soft tissue sarcoma granted orphan designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2603955592","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603955592?lang=en_us&edition=fundamental","pubTime":"2026-01-16 10:40","pubTimestamp":1768531207,"startTime":"0","endTime":"0","summary":"Lantern Pharma’s (LTRN) N-hydroxy-N(methylacylfulvene)urea was granted FDA orphan designation as a treatment of soft tissue sarcoma, according to a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lantern-pharmas-treatment-of-soft-tissue-sarcoma-granted-orphan-designation-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lantern-pharmas-treatment-of-soft-tissue-sarcoma-granted-orphan-designation-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2603014633","title":"Lake Street Remains a Buy on Lantern Pharma (LTRN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603014633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603014633?lang=en_us&edition=fundamental","pubTime":"2026-01-13 23:17","pubTimestamp":1768317435,"startTime":"0","endTime":"0","summary":"In a report released today, Chad Messer from Lake Street maintained a Buy rating on Lantern Pharma, with a price target of $25.00. According to Tip...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-remains-a-buy-on-lantern-pharma-ltrn-blurbs-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-remains-a-buy-on-lantern-pharma-ltrn-blurbs-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2602462675","title":"Lantern Pharma establishes India AI center to industrialize RADR platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2602462675","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602462675?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:32","pubTimestamp":1768228338,"startTime":"0","endTime":"0","summary":"Lantern Pharma (LTRN) announced the establishment of an AI center of excellence and advanced agentic labs in Bengaluru, India. The initiative is de...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lantern-pharma-establishes-india-ai-center-to-industrialize-radr-platform-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lantern-pharma-establishes-india-ai-center-to-industrialize-radr-platform-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LTRN","BK4543","BK4528","MNDmain","BK4585","RADR","AI","BK4587","BK4023","BK4588","BK4551"],"gpt_icon":0},{"id":"2602545858","title":"BRIEF-Lantern Pharma Inc - Establishes Ai Center Of Excellence In Bengaluru","url":"https://stock-news.laohu8.com/highlight/detail?id=2602545858","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602545858?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:08","pubTimestamp":1768226907,"startTime":"0","endTime":"0","summary":"BRIEF-Lantern Pharma Inc - Establishes Ai Center Of Excellence In BengaluruJan 12 (Reuters) - Lantern Pharma Inc LTRN.O:LANTERN PHARMA INC - ESTABLISHES AI CENTER OF EXCELLENCE IN BENGALURULANTERN PHA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0QR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2602543027","title":"Lantern Pharma Inc - Hiring Initiated, Expansion Expected to Be Cash Flow Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543027?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:06","pubTimestamp":1768226804,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0QR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LTRN"],"gpt_icon":0},{"id":"2602543000","title":"Lantern Pharma Inc - Phase 2 Focuses on Multi-Disease Expansion and Revenue Acceleration","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543000?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:06","pubTimestamp":1768226804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0QR:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LTRN"],"gpt_icon":0},{"id":"2602430765","title":"Lantern Pharma Inc - Establishes AI Center of Excellence in Bengaluru","url":"https://stock-news.laohu8.com/highlight/detail?id=2602430765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602430765?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:06","pubTimestamp":1768226804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0QR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2602543756","title":"Lantern Pharma Unveils AI Center of Excellence and Major Platform Rollout at Investor and Analyst Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543756","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543756?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:01","pubTimestamp":1768226500,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. will host an Investor and Analyst Day in New York City on January 22, 2026, at 4:00 PM ET. The event will highlight Lantern's AI Center of Excellence strategic initiative and feature the initial major rollout of its advanced platform focused on addressing underserved needs in cancer. Attendees will receive insights into Lantern's AI industrialization strategy, the expanded capabilities of the RADR platform, and the phased roadmap for deployment, as well as implications for biopharma partnerships and revenue generation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire  on January 12, 2026, and is solely responsible for","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL2W5ppZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2588678041","title":"Lantern Pharma Inc: Clinical Trial Met All Primary Endpoints for Safety, Tolerability, and Established a Clear Recommended Phase 2 Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2588678041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588678041?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:36","pubTimestamp":1764768977,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90S3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2588041343","title":"Lantern Pharma : Reports Additional Positive Lp-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2588041343","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588041343?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:36","pubTimestamp":1764768977,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90S3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2588041321","title":"Lantern Pharma Reports Positive Phase 1a Results for LP-184 in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588041321","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588041321?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:35","pubTimestamp":1764768914,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. has announced additional results from its completed Phase 1a dose-escalation clinical trial of LP-184, a biomarker-activated cancer drug candidate. The trial enrolled 63 heavily pre-treated patients with advanced solid tumors, many of whom had DNA damage repair pathway deficiencies. The study met all primary endpoints for safety and tolerability, and established a recommended Phase 2 dose. At or above therapeutic dose levels, LP-184 demonstrated a 54% disease control rate, showing encouraging efficacy signals in DNA damage repair-deficient cancers. Results from the Phase 1a study were presented in a recent company webinar, which included detailed clinical data, patient case studies, and future development plans. Lantern Pharma is advancing multiple biomarker-guided Phase 1b/2 clinical trials in indications such as triple-negative breast cancer, glioblastoma multiforme, non-small cell lung cancer, and advanced urothelial carcinoma.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLxT6VP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LTRN"],"gpt_icon":0},{"id":"2583523901","title":"Lantern Pharma’s Q3 2025: Clinical and AI Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2583523901","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583523901?lang=en_us&edition=fundamental","pubTime":"2025-11-14 12:16","pubTimestamp":1763093776,"startTime":"0","endTime":"0","summary":"Lantern Pharma, Inc. ( ($LTRN) ) has released its Q3 earnings. Here is a breakdown of the information Lantern Pharma, Inc. presented to its investo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lantern-pharmas-q3-2025-clinical-and-ai-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lantern-pharmas-q3-2025-clinical-and-ai-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065732104.USD","LTRN","BK4097","BK4139","PRGS"],"gpt_icon":0},{"id":"2583594520","title":"Lantern Pharma posts Q3 net loss of $4.2 million as LP-184 trial meets primary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2583594520","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583594520?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:26","pubTimestamp":1763047594,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. reported a net loss of $4.2 million for the third quarter of 2025, compared to a net loss of $4.5 million in the same period of 2024. Net loss per common share, basic and diluted, was $0.39, down from $0.42 in the prior year period. Total operating expenses were $4.3 million, a decrease from $5.2 million in 2024. Cash, cash equivalents, and marketable securities totaled $12.4 million as of September 30, 2025, compared to $24.0 million at the end of 2024. Total assets were $13.6 million, with total liabilities of $4.0 million and stockholders' equity of $9.6 million. Key business developments for the period included completion of the Phase 1a clinical trial for LP-184, achieving all primary endpoints with a 48% clinical benefit rate in evaluable cancer patients at or above the therapeutic dose threshold. Lantern Pharma also advanced enrollment in the first-in-human clinical trial for LP-284 in non-Hodgkin lymphoma and other cancers, and reported initial clinical data","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL9qfxgn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LTRN"],"gpt_icon":0},{"id":"2583593632","title":"Lantern Pharma Inc Qtrly Net Loss $0.39 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593632","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593632?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA4N5STD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2583931765","title":"Press Release: Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2583931765","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583931765?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040600,"startTime":"0","endTime":"0","summary":"Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Launch. --  LP-184 Phase 1a clinical trial results demonstrate all primary. endpoints achieved with 48% clinical benefit rate in evaluable cancer. patients at or above therapeutic dose threshold; marked tumor reductions. observed in patients with DNA damage repair mutations including CHK2, ATM,--  FDA Type C meeting completed, providing regulatory guidance and pathway. clarity for Starlight Therapeutics' planned pediatric CNS cancer trial in. --  LP-300 preliminary Phase 2 data presented from the HARMONIC trial. at the 66th Annual Meeting of the Japan Lung Cancer Society with further. clinical and patient data planned for a webinar in December.--  LP-284 clinical data showcased at 25th Annual Lymphoma, Leukemia &. Myeloma  Congress, generating interest from the biopharma and. clinical communities and initiating discussions for combination therapy. --  KOL-hosted","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","BK4595","BK4232","BK4587","BK4516","TM","BK4022","03160","LTRN","BK4099","AI","BK4604","R","BK4585","BK4555","BK4139","KOL","BK4023","BK4528","BK4551","BK4596","BK4588","STRK","BK4600"],"gpt_icon":1},{"id":"2583569589","title":"Lantern Pharma Q3 EPS $(0.39) Beats $(0.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583569589","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583569589?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:03","pubTimestamp":1763031801,"startTime":"0","endTime":"0","summary":"Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.54) by 27.78 percent. This is a 7.14 percent increase over losses of $(0.42) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48828383/lantern-pharma-q3-eps-0-39-beats-0-54-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN"],"gpt_icon":0},{"id":"2582730382","title":"Lantern Pharma management to meet virtually with Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2582730382","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582730382?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:25","pubTimestamp":1762961142,"startTime":"0","endTime":"0","summary":"Virtual Meeting to be held on November 20 hosted by Lake Street. Published first on TheFly – the ultimate source for real-time, market-moving break...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lantern-pharma-management-to-meet-virtually-with-lake-street-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lantern-pharma-management-to-meet-virtually-with-lake-street-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2582810885","title":"Lantern Pharma CEO Showcases AI-Driven Oncology Advances on Bloomberg","url":"https://stock-news.laohu8.com/highlight/detail?id=2582810885","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582810885?lang=en_us&edition=fundamental","pubTime":"2025-11-10 10:08","pubTimestamp":1762740510,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL7FysBz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lanternpharma.com","stockEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":0.0086},{"period":"3month","weight":-0.1348},{"period":"6month","weight":-0.1665},{"period":"1year","weight":-0.2121},{"period":"ytd","weight":0.165}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0173},{"period":"6month","weight":0.0814},{"period":"1year","weight":0.1361},{"period":"ytd","weight":0.0104}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.052254},{"month":2,"riseRate":0.4,"avgChangeRate":-0.00833},{"month":3,"riseRate":0.6,"avgChangeRate":0.157412},{"month":4,"riseRate":0.2,"avgChangeRate":-0.150119},{"month":5,"riseRate":0.6,"avgChangeRate":0.019748},{"month":6,"riseRate":0.4,"avgChangeRate":-0.03205},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.020452},{"month":8,"riseRate":0.5,"avgChangeRate":0.052764},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.071519},{"month":10,"riseRate":0,"avgChangeRate":-0.151349},{"month":11,"riseRate":0.666667,"avgChangeRate":0.098056},{"month":12,"riseRate":0.5,"avgChangeRate":0.047826}],"exchange":"NASDAQ","name":"Lantern Pharma Inc.","nameEN":"Lantern Pharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lantern Pharma Inc.(LTRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lantern Pharma Inc.(LTRN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lantern Pharma Inc.,LTRN,Lantern Pharma Inc.股票,Lantern Pharma Inc.股票老虎,Lantern Pharma Inc.股票老虎国际,Lantern Pharma Inc.行情,Lantern Pharma Inc.股票行情,Lantern Pharma Inc.股价,Lantern Pharma Inc.股市,Lantern Pharma Inc.股票价格,Lantern Pharma Inc.股票交易,Lantern Pharma Inc.股票购买,Lantern Pharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lantern Pharma Inc.(LTRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lantern Pharma Inc.(LTRN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction